94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1590955
Corrigendum: Exploring Perceived Barriers and Attitudes in Young Adults Towards Antidepressant Pharmacotherapy, Including the Implementation of Pharmacogenetic Testing to Optimize Prescription Practices
Provisionally accepted
Bradley Roberts 1,2*
Zahra Cooper 1*
Georgia Landery 1,3
Susanne Stanley 4
Bernadette Majda 5
Khan Collins 6
Patrick Anthony Akkari 1,7,8,9
Sean David Hood 1,4,6
Jennifer Rodger 1,2- 1 Perron Institute for Neurological and Translational Science, Perth, Australia
- 2 School of Biological Sciences, University of Western Australia, Perth, Western Australia, Australia
- 3 School of Biomedical Sciences, University of Western Australia, Perth, Western Australia, Australia
- 4 Division of Psychiatry, School of Medicine, University of Western Australia, Perth, Western Australia, Australia
- 5 Curtin University, Perth, Western Australia, Australia
- 6 North Metropolitan Health Service, Western Australian Department of Health, WA 6004, Australia, Perth, Australia
- 7 School of Human Sciences, University of Western Australia, Perth, Western Australia, Australia
- 8 Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth, Australia
- 9 Duke University Medical Center, Duke University, Durham, North Carolina, United States
Corrigendum: Exploring Perceived Barriers and Attitudes in Young Adults Towards Antidepressant Pharmacotherapy, Including the Implementation of Pharmacogenetic Testing to Optimize Prescription Practices* Correspondence: Bradley Roberts, brad.roberts@perron.uwa.edu.au; Zahra Cooper, zahra.cooper@perron.uwa.edu.auKeywords: same as original articleCorrigendum on: Roberts B, Cooper Z, Landery G, Stanley S, Majda BT, Collins KRL, Akkari PA, Hood SD and Rodger J (2025) Exploring perceived barriers and attitudes in young adults towards antidepressant pharmacotherapy, including the implementation of pharmacogenetic testing to optimize prescription practices. Front. Pharmacol. 15:1526101. doi: 10.3389/fphar.2024.1526101 Text CorrectionIn the published article, there was an error. A general nation-wide statistic has been stated incorrectly during changes made in the review process. Whilst the grammatical/typo error is minor in nature, this correction is necessary to stop misinformation and improper citations.A correction has been made to 1. Introduction, Paragraph 2. This sentence previously stated:“The Australian prescription rate of antidepressants has risen by ∼25% per annum over the past 7 years (Australian Institute of Health and Welfare, 2023; Australian Institute of Health and Welfare, 2022; Australian Institute of Health and Welfare, 2021a; Australian Institute of Health and Welfare, 2020; Australian Institute of Health and Welfare, 2019; Australian Institute of Health and Welfare, 2018), with over 33 million antidepressants prescribed in 2023 alone (Australian Institute of Health and Welfare, 2023).”The corrected sentence appears below:“The Australian prescription rate of antidepressants has risen by ∼33% over the past 7 years (Australian Institute of Health and Welfare, 2023; Australian Institute of Health and Welfare, 2022; Australian Institute of Health and Welfare, 2021a; Australian Institute of Health and Welfare, 2020; Australian Institute of Health and Welfare, 2019; Australian Institute of Health and Welfare, 2018), with over 33 million antidepressants prescribed in 2023 alone (Australian Institute of Health and Welfare, 2023).”The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Keywords: Pharmacogenetics, Antidepressant pharmacotherapy, depression and anxiety, Youth, young adults, Community perspective, Clinical implementation
Received: 10 Mar 2025; Accepted: 20 Mar 2025.
Copyright: © 2025 Roberts, Cooper, Landery, Stanley, Majda, Collins, Akkari, Hood and Rodger. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Bradley Roberts, Perron Institute for Neurological and Translational Science, Perth, Australia
Zahra Cooper, Perron Institute for Neurological and Translational Science, Perth, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.